Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.6% Following Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Free Report)’s share price was down 1.6% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $6.68 and last traded at $6.76. Approximately 882,144 shares traded hands during trading, a decline of 84% from the average daily volume of 5,688,068 shares. The stock had previously closed at $6.87.

Specifically, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at $3,288,380.78. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Analysts Set New Price Targets

Several analysts have recently weighed in on RXRX shares. Jefferies Financial Group decreased their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.40.

View Our Latest Stock Analysis on RXRX

Recursion Pharmaceuticals Stock Down 2.2 %

The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -4.17 and a beta of 0.80. The business’s 50-day moving average is $6.71 and its 200-day moving average is $7.68. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. During the same quarter last year, the firm posted ($0.38) EPS. The business’s revenue was up 30.9% on a year-over-year basis. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals during the 3rd quarter worth about $25,000. Farther Finance Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares in the last quarter. Finally, San Luis Wealth Advisors LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth approximately $69,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Further Reading

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.